<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Merck</title>
	<atom:link href="http://www.tapanray.in/tag/merck/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>A Link To Ponder: Pharma Digitalization – Cyber Threats &#8211; Cyber Immunity</title>
		<link>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity</link>
		<comments>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/#comments</comments>
		<pubDate>Mon, 04 Nov 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attacks]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[criminals]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[ponder]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9776</guid>
		<description><![CDATA[Digitalization in the pharmaceutical industry – slowly but steadily, across its various domains, from drug discovery, clinical development, supply chain, sales and marketing to engage with various stakeholders, is a reality today. Consequently, the concept of data as a business &#8230; <a href="http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Many Successful CEOs Don’t Want to Retire &#8211; in Pharma Too?</title>
		<link>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-many-successful-ceos-dont-want-to-retire-in-pharma-too</link>
		<comments>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/#comments</comments>
		<pubDate>Mon, 12 Nov 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[70]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Aditya]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Basudeo]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Frazier]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[HDFC]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ITC]]></category>
		<category><![CDATA[Jack]]></category>
		<category><![CDATA[Kenneth]]></category>
		<category><![CDATA[L&T]]></category>
		<category><![CDATA[listed]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[MD]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Miles]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Naik]]></category>
		<category><![CDATA[Narain]]></category>
		<category><![CDATA[Pankaj]]></category>
		<category><![CDATA[Patel]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[publicly]]></category>
		<category><![CDATA[Puri]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RBI]]></category>
		<category><![CDATA[retire]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Welsh]]></category>
		<category><![CDATA[white]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Yogeshwar]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9256</guid>
		<description><![CDATA[“On Eve of Retirement, Jack Welch Decides to Stick Around GE a Bit,” reported the Wall Street Journal (WSJ) on October 23, 2000. Nevertheless, even the legendary Jack Welsh was made no exception to GE’s mandatory retirement policy for the &#8230; <a href="http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Patient-Centricity: Emerging a C-Suite Role</title>
		<link>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-patient-centricity-emerging-a-c-suite-role</link>
		<comments>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/#comments</comments>
		<pubDate>Mon, 20 Aug 2018 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attributes]]></category>
		<category><![CDATA[C-suite]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[consistently]]></category>
		<category><![CDATA[CPO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[LEO]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pillars]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9110</guid>
		<description><![CDATA[Regardless of skepticism of many, the formidable power of physicians to take all treatment decisions for patients, is gradually getting moderated, globally. Although, its pace may vary from country to country. An increasing number of more informed patients are carving &#8230; <a href="http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Stakeholder Sentiment: Back to Square One?</title>
		<link>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-stakeholder-sentiment-back-to-square-one</link>
		<comments>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/#comments</comments>
		<pubDate>Mon, 28 May 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[guru]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximizing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[non-profit]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiment]]></category>
		<category><![CDATA[socializing]]></category>
		<category><![CDATA[square]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8965</guid>
		<description><![CDATA[Is it fair to push out the core purpose of an important process, or rather a mission, unfairly? Whether we like it or not, it happened that way, over a period of time. Way back on December 01, 1950, George W. &#8230; <a href="http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>High Innovation-Cost Makes Cancer Drugs Dear: A Fragile Argument?</title>
		<link>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument</link>
		<comments>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/#comments</comments>
		<pubDate>Mon, 18 Sep 2017 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[17]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[argument]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[bust]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[CM]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[dear]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovation-cost]]></category>
		<category><![CDATA[intensive]]></category>
		<category><![CDATA[jeopardizing]]></category>
		<category><![CDATA[Keytruda]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[policymakers]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technological]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[tribe]]></category>
		<category><![CDATA[unaffordable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8417</guid>
		<description><![CDATA[Cancer is a major cause of high morbidity and mortality in India, just many other countries, according to a report of the World Health Organization (W.H.O). While deaths from cancer worldwide are projected to continue to rise to over 1.31 &#8230; <a href="http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Stakeholder-Mix Has Changed, But Pharma Marketing Has Not</title>
		<link>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-stakeholder-mix-has-changed-but-pharma-marketing-has-not</link>
		<comments>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/#comments</comments>
		<pubDate>Mon, 13 Jun 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[captains]]></category>
		<category><![CDATA[category]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[multi-stakeholder]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recasting]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7670</guid>
		<description><![CDATA[“We try never to forget that medicine is for the people. It is not for profit. Profits follow, and if we have remembered that, they never fail to appear.” In 1952, George Wilhelm Herman Emanuel Merck, the then President of &#8230; <a href="http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Digital Marketing: Is Pharma Still A Laggard?</title>
		<link>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=digital-marketing-is-pharma-still-a-laggard</link>
		<comments>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/#comments</comments>
		<pubDate>Mon, 17 Aug 2015 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Cephalon]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Freebies]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[laggard]]></category>
		<category><![CDATA[Maggi]]></category>
		<category><![CDATA[Maggie]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Salford Business School]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCB]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6946</guid>
		<description><![CDATA[‘Brand Marketing’ in the pharmaceutical industry, across the world, has mostly remained tradition bound, despite its rapid embracement of modern state of the art tools and technology in most other areas of the business. Many other industries have been demonstrating &#8230; <a href="http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quantum Value Addition With Health Apps, Going Beyond Drugs</title>
		<link>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quantum-value-addition-with-health-apps-going-beyond-drugs</link>
		<comments>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/#comments</comments>
		<pubDate>Mon, 30 Mar 2015 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Betaseron]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[hardware]]></category>
		<category><![CDATA[Health Apps]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[mApps]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[myBETAapp]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Podhaler Pro]]></category>
		<category><![CDATA[Pradaxa Health App]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[software]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tracker]]></category>
		<category><![CDATA[Xarelto Patient Care App]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6475</guid>
		<description><![CDATA[Besides all important brand attributes and how well those are communicated to the doctors, the &#8216;game winning&#8217; differentiating factors in the prescription drug business, as it appears today, would revolve around overall quality of patient-centric approach and offerings of pharma &#8230; <a href="http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Patient-Centric State Initiative To Revolutionize Disease Treatment</title>
		<link>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-patient-centric-state-initiative-to-revolutionize-disease-treatment</link>
		<comments>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/#comments</comments>
		<pubDate>Mon, 09 Feb 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[DCAT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Smith]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[William]]></category>
		<category><![CDATA[‘Moonshot’ Medicine Will Let Us Down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6374</guid>
		<description><![CDATA[In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop &#8220;Precision Medicine&#8221; in his country – a bold, giant and perhaps unprecedented State initiative to &#8230; <a href="http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Paying For The Best Health Outcomes At The Lowest Possible Cost</title>
		<link>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=paying-for-the-best-health-outcomes-at-the-lowest-possible-cost</link>
		<comments>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/#comments</comments>
		<pubDate>Mon, 08 Dec 2014 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Burrill]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[Gallup]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Levitra (vardenafil)]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Michael Porter]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[OBP]]></category>
		<category><![CDATA[Outcomes. Lowest]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[QALY]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thomas Lee]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>
		<category><![CDATA[Velcade (bortezomib)]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6244</guid>
		<description><![CDATA[“Bayer CEO Dr. Marijn Dekkers is happy to have fair Outcomes-Based Pricing”, reported ‘PharmaTimes’ on December 3, 2014. Dr. Dekkers was quoted saying, “It is okay to be tested on that in the process of price-setting, that is fine, we should &#8230; <a href="http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
